On June 18, Alibaba Health fell 3.27% in regular trading, trading at HK$3.26/share, with turnover of HK$263 million. The stock has weakened for three consecutive trading sessions.

On the news front, persistent global liquidity tightening signals have weighed on Hong Kong-listed technology and healthcare stocks, with analysts expecting the Fed's next policy move could be a rate hike. Additionally, the company announced on June 15 the grant of approximately 56.46 million restricted share units and 2.28 million share options to 521 grantees under its share award plan, with potential dilution effects drawing market attention.

Within the Internet and Direct Marketing Retail sector, peers declined broadly. Among individual stocks, PA Good Doctor fell 4.10%, BABA-W fell 3.84%, Meituan fell 3.49%, JD-SW fell 2.52%, and JD Health fell 1.86%, reflecting continued sector-wide weakness.

Alibaba Health Information Technology Limited is Alibaba Group's flagship platform in the healthcare sector, primarily engaged in pharmaceutical and health product sales, operating a pharmaceutical e-commerce platform and consumer healthcare services platform.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)